Reported about 14 hours ago
This article examines Exelixis, Inc. (NASDAQ:EXEL) in the context of Jim Simons’ Renaissance Technologies investment strategies. Despite the firm's focus on quantitative analysis and impressive returns over the years, Exelixis ranks 9th among its top stock picks. The company specializes in targeted cancer therapies and has recently achieved FDA approval for a cancer treatment. Although it has shown steady growth, analysts suggest broader AI stocks may offer better investment potential.
Source: YAHOO